- Home
- GF vs MCRB Comparison
GF vs MCRB Comparison
Compare GF & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GF
- MCRB
- Stock Information
- Founded
- GF 1990
- MCRB 2010
- Country
- GF Germany
- MCRB United States
- Employees
- GF N/A
- MCRB N/A
- Industry
- GF Investment Managers
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- GF Finance
- MCRB Health Care
- Exchange
- GF Nasdaq
- MCRB Nasdaq
- Market Cap
- GF 126.8M
- MCRB 131.0M
- IPO Year
- GF N/A
- MCRB 2015
- Fundamental
- Price
- GF $8.09
- MCRB $0.73
- Analyst Decision
- GF
- MCRB Buy
- Analyst Count
- GF 0
- MCRB 4
- Target Price
- GF N/A
- MCRB $5.63
- AVG Volume (30 Days)
- GF 28.1K
- MCRB 2.0M
- Earning Date
- GF 01-01-0001
- MCRB 03-04-2025
- Dividend Yield
- GF 0.82%
- MCRB N/A
- EPS Growth
- GF N/A
- MCRB N/A
- EPS
- GF N/A
- MCRB N/A
- Revenue
- GF N/A
- MCRB $126,325,000.00
- Revenue This Year
- GF N/A
- MCRB N/A
- Revenue Next Year
- GF N/A
- MCRB N/A
- P/E Ratio
- GF N/A
- MCRB N/A
- Revenue Growth
- GF N/A
- MCRB 12856.41
- 52 Week Low
- GF $7.38
- MCRB $0.54
- 52 Week High
- GF $9.41
- MCRB $1.53
- Technical
- Relative Strength Index (RSI)
- GF 55.14
- MCRB 37.88
- Support Level
- GF $7.84
- MCRB $0.71
- Resistance Level
- GF $8.05
- MCRB $0.91
- Average True Range (ATR)
- GF 0.08
- MCRB 0.06
- MACD
- GF 0.03
- MCRB -0.02
- Stochastic Oscillator
- GF 92.11
- MCRB 8.37
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a United States-based non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.